Tag: human serum albumin market trends

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Human Serum Albumin Market Forecast: Value Set To Climb From $6.21 Billion To $8.15 Billion

The human serum albumin market size has experienced robust expansion in recent years. It is projected to increase from $5.79 billion in 2025 to $6.21 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. The market’s historical growth can be attributed to the limited availability of recombinant hsa, reliance on plasma-derived hsa, growing hospital and clinical demand, increasing use in diagnostic and therapeutic applications, and the adoption of standard injection solutions.

The human serum albumin market size is anticipated to experience robust expansion in the coming years. It is projected to reach $8.16 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This predicted growth is primarily driven by factors such as the advancements in yeast, bacterial, and plant-based recombinant hsa development, an increasing need for fatty acid-free formulations, the broadening scope of drug delivery and nutrition enhancement uses, greater investments in research laboratories, and increased procurement by hospitals and blood banks. Key trends anticipated during this period encompass a heightened demand for both plasma-derived and recombinant human serum albumin, an expanded application of hsa in volume expanders and drug delivery systems, the growing preference for lyophilized powder and injection solutions, wider use in hospital and research laboratory settings, and a particular emphasis on fatty acid-free and specialized hsa preparations.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=27310&type=smp&name=Human%20Serum%20Albumin%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Human Serum Albumin Market Growth Backed By Core Demand Fundamentals

The human serum albumin market is anticipated to expand due to the rising occurrence of liver ailments. These conditions encompass a range of issues that compromise liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. A key contributor to the surge in liver diseases is the growing rate of obesity, with surplus abdominal fat often resulting in non-alcoholic fatty liver disease (NAFLD), which involves fat buildup, inflammation, and can potentially lead to liver failure. Human serum albumin offers therapeutic benefits for liver disease patients by restoring blood volume, mitigating fluid accumulation, safeguarding kidney function, and enhancing prognoses for complications like ascites and hepatorenal syndrome. As an illustration, a report issued by the Office for Health Improvement and Disparities, a UK-based government body, indicated in December 2024 that premature fatalities from alcoholic liver disease saw a 3.6% rise in 2023, totaling 5,984 cases, up from 5,776 in 2022. Consequently, the expanding incidence of liver diseases is a significant impetus behind the growth of the human serum albumin market.

Human Serum Albumin Market Segment Outlook: Which Categories Are Growing Fastest?

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

Human Serum Albumin Market Growth Trends Reshaping The Competitive Landscape

Leading companies within the human serum albumin market are prioritizing the development of innovative solutions, such as animal-free recombinant excipients. This focus aims to bolster product safety, enhance scalability, and ensure compliance with regulatory standards across biomanufacturing applications. An animal-free recombinant excipient is defined as a biologically engineered inactive substance, synthesized using recombinant DNA technology, that is entirely free from animal or human-derived components, thereby guaranteeing high purity and safety in both pharmaceutical and biomanufacturing contexts. As an example, in April 2025, InVitri Inc., a US-based provider specializing in animal-free recombinant proteins and excipients, introduced Optibumin 25. This product marks the first recombinant 25% human serum albumin specifically formulated for closed-system biomanufacturing. It has been optimized for various workflows including downstream processing, formulation, and cryopreservation, and is currently supplied in 100 mL single-use bags. Its chemically defined and animal-origin-free composition assures superior purity, consistency, and reduced risks of contamination. Furthermore, it is GMP-ready, capable of scaling to commercial production volumes, and delivers a stable, sterile solution that seamlessly integrates into critical applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Human Serum Albumin Market Leading Companies And Competitive Benchmarking

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

View The Full Human Serum Albumin Market Report:

https://thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Human Serum Albumin Market Geographic Analysis: Where Is Demand Accelerating Fastest?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Human Serum Albumin Market Size Forecast: How Large Could The Market Become By 2030?

The human serum albumin market has seen notable expansion over the past few years. Projections indicate it will increase from $5.79 billion in 2025 to $6.21 billion in 2026, driven by a compound annual growth rate of 7.3%. During the historic period, this growth was fueled by the restricted supply of recombinant HSA, a heavy dependence on plasma-derived HSA, rising demand from hospitals and clinical settings, broader utilization in diagnostic and therapeutic applications, and the uptake of standard injection solutions.

The human serum albumin market is projected to experience robust expansion over the coming years, with its value anticipated to reach $8.16 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.0%. This forecasted growth is fueled by several key factors, including the advancement of recombinant HSA derived from yeast, bacteria, and plants; a heightened demand for formulations free of fatty acids; the broadening of applications in drug delivery and nutritional enhancement; increased funding for research laboratories; and expanded procurement activities in hospitals and blood banks. Among the predominant trends shaping the market during this period are a growing preference for both plasma-derived and recombinant human serum albumin, an uptick in HSA utilization within volume expanders and drug delivery mechanisms, a greater reliance on lyophilized powders and injectable solutions, an expansion of its use across hospital and research laboratory settings, and a concentrated effort on developing specialty and fatty acid-free HSA preparations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Human Serum Albumin Market Demand Drivers: What Is Fueling Industry Growth?

The rising incidence of liver disorders is anticipated to drive expansion in the human serum albumin market in the coming period. Liver diseases encompass a range of conditions that compromise hepatic function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. This uptick in liver ailments stems from the growing prevalence of obesity, where excess abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), resulting in fat buildup, inflammation, and the potential for liver failure. Human serum albumin aids in managing liver disease by restoring blood volume, alleviating fluid retention, protecting renal function, and enhancing outcomes in complications like ascites and hepatorenal syndrome. As an example, a report from December 2024 by the Office for Health Improvement and Disparities, a UK government agency, indicated that premature deaths due to alcoholic liver disease rose by 3.6% in 2023, totaling 5,984 cases compared to 5,776 in 2022. Consequently, the growing prevalence of liver diseases is fueling the growth of the human serum albumin market.

Human Serum Albumin Market Segmentation And Category Breakdown

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

Human Serum Albumin Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading companies in the human serum albumin market are concentrating on developing advanced solutions, including animal-free recombinant excipients, aimed at improving product safety, scalability, and adherence to regulatory standards in biomanufacturing. An animal-free recombinant excipient is a biologically engineered inactive substance produced using recombinant DNA technology that contains no components derived from animals or humans, providing high purity and safety in pharmaceutical and biomanufacturing settings. For example, in April 2025, InVitri Inc., a U.S.-based company specializing in animal-free, recombinant proteins and excipients, introduced Optibumin 25, the first recombinant 25% human serum albumin intended for closed-system biomanufacturing. This product is specifically engineered for closed-system processes, optimized for downstream processing, formulation, and cryopreservation workflows, and is offered in 100 mL single-use bags. Its animal-origin-free and chemically defined composition ensures high purity, consistency, and lower contamination risks. Being GMP-ready and scalable to commercial production levels, it delivers a stable, sterile solution that integrates smoothly into applications like viral vector production, stem cell preservation, vaccine formulation, and more.

Human Serum Albumin Market Competitive Analysis Of Major Industry Participants

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Access The Complete Human Serum Albumin Market Report:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Human Serum Albumin Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Human Serum Albumin Market Over The Forecast Period?

The human serum albumin market has demonstrated substantial growth over recent years. It is anticipated to expand from $5.79 billion in 2025 to $6.21 billion in 2026, registering a compound annual growth rate (CAGR) of 7.3%. This past growth can be attributed to factors such as the constrained availability of recombinant HSA, the ongoing reliance on plasma-derived HSA, increasing demand from hospitals and clinical settings, its rising application in diagnostic and therapeutic procedures, and the adoption of standard injection solutions.

The human serum albumin market is anticipated to experience robust growth in the coming years. It is projected to expand to $8.16 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is driven by factors such as the development of yeast, bacterial, and plant-based recombinant hsa, an increasing demand for fatty acid-free formulations, the widening application in drug delivery and nutrition enhancement, greater investment in research laboratories, and increased procurement by hospitals and blood banks. Prominent trends observed in this period include a rising demand for both plasma-derived and recombinant human serum albumin, an expanded use of hsa in volume expanders and drug delivery systems, growing adoption of lyophilized powder and injection solutions, the expansion of applications in hospital and research laboratories, and a focus on fatty acid-free and specialty hsa preparations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Which Strategic Drivers Are Supporting The Human Serum Albumin Market Development?

The growing incidence of liver ailments is anticipated to drive expansion in the human serum albumin market. These conditions encompass various disorders that compromise liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases stems from the increasing rates of obesity, given that excessive abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), which can result in fat buildup, inflammation, and eventual liver failure. Human serum albumin aids in managing liver disease by restoring blood volume, minimizing fluid retention, safeguarding kidney function, and enhancing prognoses in related complications like ascites and hepatorenal syndrome. As an illustration, a report issued in December 2024 by the Office for Health Improvement and Disparities, a UK government agency, indicated a 3.6% rise in premature fatalities from alcoholic liver disease in 2023, totaling 5,984 cases against 5,776 in 2022. Consequently, the escalating occurrence of liver conditions is fueling the expansion of the human serum albumin market.

Which Segment Groups Define The Human Serum Albumin Market Landscape?

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

What Trends Are Driving Changes In The Human Serum Albumin Market?

Major companies in the human serum albumin market are concentrating on developing innovative solutions, such as animal-free recombinant excipients, to boost product safety, scalability, and adherence to regulatory standards in biomanufacturing applications. An animal-free recombinant excipient refers to a biologically engineered inactive substance created using recombinant DNA technology without any animal or human-derived components, ensuring high purity and safety in pharmaceutical and biomanufacturing applications. For instance, in April 2025, InVitri Inc., a US-based provider of animal-free, recombinant proteins and excipients, launched Optibumin 25, the first recombinant 25% human serum albumin for closed-system biomanufacturing. This product is the first recombinant 25% human serum albumin specifically designed for closed-system biomanufacturing. It is optimized for downstream processing, formulation, and cryopreservation workflows, and is currently available in 100 mL single-use bags. With its animal-origin-free and chemically defined composition, it ensures high purity, consistency, and reduced contamination risks. It is GMP-ready, scalable to commercial production volumes, and offers a stable, sterile solution that integrates seamlessly into applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Which Companies Are Engaged In The Human Serum Albumin Market Environment?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Access The Complete Human Serum Albumin Market Report:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

What Is The Largest Regional Market In The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Human Serum Albumin Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company

Wall Decor Market Report 2026

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Market Report 2026

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Human Serum Albumin Market During 2026–2030?

The human serum albumin market has experienced significant growth in recent years. It is anticipated to expand from $5.79 billion in 2025 to $6.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to factors such as the limited availability of recombinant hsa, the ongoing reliance on plasma-derived hsa, rising hospital and clinical demand, the increasing application in diagnostic and therapeutic fields, and the widespread adoption of standard injection solutions.

The human serum albumin market size is anticipated to demonstrate robust growth in the upcoming years. It is projected to expand to $8.16 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is attributable to the development of yeast, bacterial, and plant-based recombinant HSA, an increasing demand for fatty acid-free formulations, the broadening of drug delivery and nutrition enhancement applications, rising investment in research laboratories, and increased procurement by hospitals and blood banks. Significant trends expected in the forecast period include a growing demand for both plasma-derived and recombinant human serum albumin, an expanding utilization of HSA in volume expanders and drug delivery systems, the increasing adoption of lyophilized powder and injection solutions, the expansion of its uses in hospital and research laboratory applications, and a focus on fatty acid-free and specialty HSA preparations.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Which Factors Are Influencing The Growth Of The Human Serum Albumin Market?

The rising occurrence of liver conditions is anticipated to fuel the expansion of the human serum albumin market moving ahead. These diseases encompass various ailments that compromise liver performance, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases stems from the growing incidence of obesity, where surplus abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), resulting in fat buildup, inflammation, and potential organ failure. Human serum albumin aids in managing liver disease by re-establishing blood volume, diminishing fluid retention, safeguarding renal function, and enhancing results in complications like ascites and hepatorenal syndrome. As an illustration, a report released in December 2024 by the Office for Health Improvement and Disparities, a UK government body, indicated that premature fatalities attributed to alcoholic liver disease saw a 3.6% rise in 2023, totaling 5,984 cases, up from 5,776 in 2022. Consequently, the expanding occurrence of liver illnesses is stimulating the growth of the human serum albumin market.

How Is The Human Serum Albumin Market Categorized Across Its Segment Groups?

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

Which Trends Are Influencing Demand In The Human Serum Albumin Market?

Companies operating within the human serum albumin market are concentrating on developing innovative solutions, such as animal-free recombinant excipients, to boost product safety, scalability, and compliance with regulatory requirements in biomanufacturing applications. An animal-free recombinant excipient is an inactive substance, biologically engineered through recombinant DNA technology without any animal or human-derived components, thereby ensuring high purity and safety for pharmaceutical and biomanufacturing uses. As an example, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, unveiled Optibumin 25, the first recombinant 25% human serum albumin specifically for closed-system biomanufacturing. This product is optimized for downstream processing, formulation, and cryopreservation workflows, and is currently supplied in 100 mL single-use bags. With its animal-origin-free and chemically defined makeup, it provides high purity, consistency, and reduced risks of contamination. It is GMP-ready, scalable for commercial production, and offers a stable, sterile solution that easily integrates into applications like viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Which Firms Are Influencing Competition In The Human Serum Albumin Market?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Get The Full Human Serum Albumin Market Report:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

Which Region Has The Greatest Market Share In The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Human Serum Albumin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company

Wall Decor Market Report 2026

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Market Report 2026

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Human Serum Albumin Market Over The 2026–2030 Period?

The human serum albumin market size has experienced significant growth in recent years. It is anticipated to expand from $5.79 billion in 2025 to $6.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The historical increase can be ascribed to factors including the limited availability of recombinant HSA, reliance on plasma-derived HSA, rising hospital and clinical demand, increasing utilization in diagnostic and therapeutic applications, and the adoption of standard injection solutions.

The human serum albumin market is projected for robust expansion in the coming years, with its size forecast to reach $8.16 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This anticipated growth is largely fueled by the advancements in yeast, bacterial, and plant-based recombinant hsa development, alongside an escalating demand for fatty acid-free formulations. Further contributions come from the broadening scope of drug delivery and nutrition enhancement applications, increased investment in research laboratories, and greater procurement by hospitals and blood banks. Key trends during this period are expected to encompass a surging demand for both plasma-derived and recombinant human serum albumin, a greater utilization of hsa in volume expanders and drug delivery systems, and an uptick in the adoption of lyophilized powder and injection solutions. Additionally, the market will observe an expansion of applications within hospitals and research laboratories, alongside a heightened focus on fatty acid-free and specialty hsa preparations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Which Major Factors Are Driving The Expansion Of The Human Serum Albumin Market?

The human serum albumin market is expected to grow due to the increasing incidence of liver diseases. These conditions involve a range of disorders that impair liver function, including hepatitis, fatty liver disease, cirrhosis, and liver cancer. The rise in liver diseases is attributed to the growing prevalence of obesity, as excess abdominal fat can lead to non-alcoholic fatty liver disease (NAFLD), causing fat accumulation, inflammation, and potential liver failure. Human serum albumin assists in managing liver disease by restoring blood volume, reducing fluid accumulation, protecting kidney function, and improving outcomes in complications such as ascites and hepatorenal syndrome. For instance, a report published in December 2024 by the Office for Health Improvement and Disparities, a UK-based government agency, revealed that premature deaths from alcoholic liver disease increased by 3.6% in 2023, reaching 5,984 cases compared with 5,776 in 2022. Therefore, the increasing prevalence of liver diseases is driving the growth of the human serum albumin market.

How Is The Human Serum Albumin Market Segmented Across Key Categories?

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

Which Upcoming Trends Are Expected To Influence The Human Serum Albumin Market?

Companies operating in the human serum albumin market are prioritizing the creation of advanced solutions, such as animal-free recombinant excipients, to improve product safety, ensure scalability, and comply with regulatory requirements in biomanufacturing applications. An animal-free recombinant excipient is defined as a biologically engineered, inactive substance produced through recombinant DNA technology without any animal- or human-derived components, thereby guaranteeing high purity and safety in pharmaceutical and biomanufacturing uses. For example, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, unveiled Optibumin 25, the first recombinant 25% human serum albumin specifically designed for closed-system biomanufacturing. This product is optimized for downstream processing, formulation, and cryopreservation workflows, and is presently available in 100 mL single-use bags. Its animal-origin-free and chemically defined composition ensures superior purity, consistency, and reduced contamination risks. Furthermore, it is GMP-ready, scalable to commercial production volumes, and offers a stable, sterile solution that integrates effortlessly into applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Who Are The Dominant Players Shaping The Human Serum Albumin Market Landscape?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Read the full human serum albumin market report here:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

Which Region Currently Holds The Largest Share Of The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Human Serum Albumin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company

Wall Decor Market Report 2026

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Market Report 2026

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the human serum albumin market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Human Serum Albumin Market’s size between 2026 and 2030?

The human serum albumin market size has seen robust expansion in recent years. It is anticipated to increase from $5.79 billion in 2025 to $6.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The historical period’s growth can be linked to the limited availability of recombinant hsa, a reliance on plasma-derived hsa, increasing demand from hospitals and clinical settings, expanded application in diagnostic and therapeutic fields, and the adoption of standard injection solutions.

The human serum albumin market size is poised for robust expansion over the next few years, with projections indicating it will reach $8.16 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.0%. This anticipated growth is fueled by the development of yeast, bacterial, and plant-based recombinant hsa, an increasing need for fatty acid-free formulations, the widening application in drug delivery and nutrition enhancement, increased funding in research laboratories, and a rise in procurement from hospitals and blood banks. Significant trends during this forecast period include a surging demand for plasma-derived and recombinant human serum albumin, the increased utilization of hsa in volume expanders and drug delivery systems, a growing adoption of lyophilized powder and injection solutions, the expansion of its use in hospital and research laboratory environments, and an emphasis on fatty acid-free and specialized hsa preparations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Which Drivers Are Shaping Strategic Decisions In The Human Serum Albumin Market?

The escalating occurrence of liver ailments is projected to boost the expansion of the human serum albumin market in the future. These conditions encompass a range of disorders that hinder liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The rise in liver diseases stems from the growing incidence of obesity, where excessive abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), leading to fat accumulation, inflammation, and potential liver failure. Human serum albumin aids in managing liver disease by re-establishing blood volume, mitigating fluid retention, safeguarding kidney function, and enhancing results in complications like ascites and hepatorenal syndrome. A notable example occurred in December 2024, when a report from the Office for Health Improvement and Disparities, a UK government body, indicated a 3.6% increase in premature deaths from alcoholic liver disease in 2023, totaling 5,984 cases, up from 5,776 in 2022. Consequently, the growing incidence of liver conditions is fueling the expansion of the human serum albumin market.

What Segment Categories Are Covered In The Human Serum Albumin Market?

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

How Are New Market Trends Shaping The Landscape Of The Human Serum Albumin Market?

Leading companies within the human serum albumin market are concentrating on developing novel solutions, like animal-free recombinant excipients, to improve product safety, expand scalability, and ensure adherence to regulatory requirements in biomanufacturing. An animal-free recombinant excipient is an inactive, biologically engineered substance created through recombinant DNA technology, completely free of animal or human components, guaranteeing high purity and safety for pharmaceutical and biomanufacturing uses. For instance, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, introduced Optibumin 25, which is the inaugural recombinant 25% human serum albumin for closed-system biomanufacturing. This product is optimized for workflows in downstream processing, formulation, and cryopreservation, and is presently offered in 100 mL single-use bags. Its animal-origin-free and chemically defined composition ensures superior purity, consistency, and minimizes contamination risks. Being GMP-ready and scalable to commercial production volumes, it provides a stable, sterile solution that seamlessly integrates into various applications, including viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Which Key Market Players Are Investing In Expansion And Innovation Within The Human Serum Albumin Market?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

Which Regions Are Poised For Strategic Growth In The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Human Serum Albumin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company

Wall Decor Market Report 2026

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Market Report 2026

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the human serum albumin market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Human Serum Albumin Market Be Worth By 2029?

The human serum albumin market has experienced significant growth in recent years. It is anticipated to increase from $5.39 billion in 2024 to $5.79 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.5%. The expansion witnessed in the past can be attributed to several factors including rising healthcare demand, the broadening uses of human serum albumin, an expanding elderly population, an escalating need for blood plasma derivatives, and the increasing incidence of liver disorders and related conditions.

The human serum albumin market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $7.63 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period is primarily driven by factors such as increased availability of essential medicines, broader therapeutic applications, an increase in hospital numbers, enhanced healthcare infrastructure, and various governmental initiatives. Key trends influencing this period encompass cell-free protein synthesis, CRISPR-based strain engineering, the adoption of continuous manufacturing techniques, the development of transdermal delivery systems, and progress in lyophilization.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

What External And Internal Drivers Are Influencing The Human Serum Albumin Market?

The human serum albumin market is projected to expand due to the escalating incidence of liver diseases. These conditions, which impair liver function, encompass hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases is attributed to the growing prevalence of obesity, as excess abdominal fat often results in non-alcoholic fatty liver disease (NAFLD), characterized by fat buildup, inflammation, and potential liver failure. Human serum albumin plays a crucial role in managing liver disease by restoring blood volume, mitigating fluid retention, safeguarding kidney function, and enhancing outcomes in associated complications such as ascites and hepatorenal syndrome. For instance, data from a report issued by the Office for Health Improvement & Disparities in July 2023 indicated a 22.0% increase in UK hospital admissions where liver disease was the primary diagnosis, climbing from 67,458 cases in 2021 to 82,290 cases in 2022. Consequently, the rising occurrence of liver diseases is a key driver for the human serum albumin market’s growth.

What Segmentation Insights Are Provided In The Human Serum Albumin Market Research?

The human serum albumin market covered in this report is segmented

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

Which Notable Trends Are Transforming The Human Serum Albumin Market Outlook?

Major companies operating in the human serum albumin market are actively pursuing the creation of innovative solutions, specifically animal-free recombinant excipients. These developments aim to improve product safety, ensure scalability, and meet regulatory requirements for biomanufacturing processes. An animal-free recombinant excipient is defined as a biologically engineered inactive substance, developed using recombinant DNA technology, entirely devoid of animal or human components, thereby guaranteeing high levels of purity and safety in both pharmaceutical and biomanufacturing contexts. As an illustration, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, introduced Optibumin 25 in April 2025. This product stands as the first recombinant 25% human serum albumin developed for closed-system biomanufacturing. It is precisely optimized for processes like downstream processing, formulation, and cryopreservation workflows, and is currently offered in 100 mL single-use bags. Its composition, being free of animal origin and chemically defined, ensures exceptional purity, consistency, and minimizes the potential for contamination. Furthermore, it is GMP-ready, capable of scaling to commercial production volumes, and presents a stable, sterile solution that readily integrates into diverse applications, including viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Who Are The Leading Companies Driving The Human Serum Albumin Market?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols S A, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2025, By The Business Research Company

Wall Decor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Commercial Flooring Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Exterior Wall Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/exterior-wall-systems-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Human Serum Albumin Market Over The Five-Year Period 2025–2029?

The human serum albumin market has demonstrated substantial expansion over recent years. This market is projected to expand from $5.39 billion in 2024 to $5.79 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 7.5%. Historically, this expansion has been driven by factors such as a rise in healthcare needs, the broadening uses of human serum albumin, a growing elderly population, heightened demand for blood plasma derivatives, and an increase in liver conditions and associated diseases.

The human serum albumin market is projected to experience substantial expansion in the coming years, reaching $7.63 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.1%. This anticipated growth during the forecast period is due to factors such as increased availability of crucial medications, wider-ranging therapeutic uses, an increasing count of hospitals, developing healthcare infrastructure, and governmental efforts. Key developments expected in the forecast period encompass cell-free protein synthesis, CRISPR-based strain engineering, adoption of continuous manufacturing techniques, innovations in transdermal delivery systems, and progress in lyophilization.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

What Are The Key Drivers Of Growth In The Human Serum Albumin Market?

The anticipated rise in liver disease cases is set to boost the human serum albumin market in the coming years. Liver diseases encompass various ailments that compromise liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases is primarily linked to the increasing rates of obesity, as excessive abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), leading to fat buildup, inflammation, and potential liver failure. Human serum albumin assists in managing liver disease by reestablishing blood volume, reducing fluid retention, protecting renal function, and improving prognoses for complications like ascites and hepatorenal syndrome. Illustratively, a July 2023 publication by the Office for Health Improvement & Disparities, a UK government department, revealed that hospital admissions where liver disease was the primary diagnosis saw a 22.0% increase in the financial year ending 2022, climbing from 67,458 cases in 2021 to 82,290 cases in 2022. Consequently, the increasing prevalence of liver diseases is a significant driver for the human serum albumin market.

What Are The Segment Types Shaping The Human Serum Albumin Market?

The human serum albumin market covered in this report is segmented

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

How Are Emerging Market Trends Shaping The Human Serum Albumin Industry Landscape?

Major companies operating in the human serum albumin market are increasingly focusing on creating advanced solutions, particularly animal-free recombinant excipients, to bolster product safety, expand scalability, and ensure compliance with regulatory frameworks in biomanufacturing processes. An animal-free recombinant excipient refers to an inactive biological substance engineered using recombinant DNA technology, devoid of any animal- or human-derived ingredients, thus guaranteeing high purity and safety in pharmaceutical and biomanufacturing contexts. For example, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, launched Optibumin 25, which is the first recombinant 25% human serum albumin developed for closed-system biomanufacturing. This product is specifically optimized for downstream processing, formulation, and cryopreservation workflows, and is presently available in 100 mL single-use bags. Its animal-origin-free and chemically defined composition contributes to superior purity, consistency, and minimized contamination hazards. It is also GMP-ready, scalable for commercial production volumes, and offers a stable, sterile solution that seamlessly integrates into applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Who Are The Primary Competitors In The Global Human Serum Albumin Market?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols S A, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

How Is Human Serum Albumin Market Demand Varying Across Different Regions?

North America was the largest region in the human serum albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Human Serum Albumin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2025, By The Business Research Company

Wall Decor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Human Serum Albumin Market Expected to Be in 2029?

The market size for human serum albumin has seen robust growth in recent years. The market is projected to increase from $5.39 billion in 2024 to $5.79 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. Factors such as growing healthcare requirements, broader uses of human serum albumin, an aging demographic, rising demand for blood plasma derivatives, and an increase in liver disorders and related diseases have contributed to the growth during the history term.

In the coming years, a significant expansion is forecasted for the human serum albumin market. It is anticipated to reach $7.63 billion by 2029, growing at a compound annual rate (CAGR) of 7.1%. This growth during the forecast period is due to factors including increased access to essential medicines, wider therapeutic usage, burgeoning hospital numbers, developing healthcare facilities and government-driven initiatives. Key trends foreseen during this period involve cell-free protein production, CRISPR-genome engineered strains, ongoing manufacturing methodologies, transdermal delivery mechanisms and advancements in lyophilization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

What Are The Contributors To Demand In The Human Serum Albumin Market?

With liver diseases becoming increasingly rampant, the human serum albumin market is expected to witness substantial growth. Diseases that impair liver function such as cirrhosis, hepatitis, fatty liver disease, and liver cancer are classified under liver diseases. The surge in liver diseases is a direct result of the growing incidence of obesity, which in turn leads to non-alcoholic fatty liver disease (NAFLD), characterized by fat deposition, inflammation, and possible liver failure due to excess abdominal fat. Human serum albumin contributes to combating liver disease by boosting blood volume, reducing fluid accumulation, ensuring kidney function, and enhancing outcomes in complications like ascites and hepatorenal syndrome. A report released in July 2023 by the Office for Health Improvement & Disparities, a UK government department, indicates an increase of 22.0% in hospital admissions with liver disease as the primary diagnosis in the fiscal year ending 2022, with cases going up from 67,458 in 2021 to 82,290 in 2022. Hence, the rising incidence of liver diseases is propelling the growth of the human serum albumin market.

What Segmentation Categories Are Included In The Human Serum Albumin Market Analysis?

The human serum albumin market covered in this report is segmented

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

What Upcoming Trends Are Expected To Impact The Human Serum Albumin Market Globally?

Leading organizations active in the human serum albumin market are concentrating on the development of novel solutions, including animal-free recombinant excipients, to advance product safety, scalability, and adherence to regulatory guidelines in biomanufacturing applications. The term animal-free recombinant excipient pertains to a biologically manipulated inactive substance produced utilizing recombinant DNA technology that does not contain any components derived from animals or humans, thereby guaranteeing high purity and safety in applications related to pharmaceutical and biomanufacturing. For example, in April 2025, InVitri Inc., a company based in the US that supplies animal-free, recombinant proteins, and excipients, introduced Optibumin 25, the premier recombinant 25% human serum albumin in closed-system biomanufacturing. This particular human serum albumin has been specifically created for closed-system biomanufacturing and is designed for downstream processing, formulation, and cryopreservation practices. It is now obtainable in 100 mL single-use packets. Its composition, defined chemically and free of animal origin, assures high purity, consistency, and minimizes the risk of contamination. It is ready for GMP, scalable for large-scale production, and provides a steady, sterile solution that effortlessly assimilates into applications like viral vector production, stem cell conservation, vaccine development, and regenerative medical practices.

Who Are The Top-Ranked Companies In The Human Serum Albumin Market Today?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols S A, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

How Is Human Serum Albumin Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the human serum albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model